Therapeutic inhibition of thrombin activities, receptors, and production

Hematology/Oncology Clinics of North America

Volumn 12, Issue 6, 1998, Pages 1211-1230

  Harker, L A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE; THROMBIN INHIBITOR;

ANTICOAGULATION; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; FIBRINOLYSIS; GENE TARGETING; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; VEIN THROMBOSIS;

EID: 0032413117     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70050-2     Document Type: Article

References (86)

1. G. Agnelli C. Pascucci B. Cosmi The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits Thromb Haemost 63 1990 204
2. E.M. Antman Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial Circulation 94 1996 911
3. E.M. Antman TIMI 9A Investigators: Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial Circulation 90 1994 1624
4. B.J. Beimond P.W. Friederich M. Levi Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis Circulation 93 1996 153
5. C.R. Benedict J. Ryan B. Wolitzky Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model J Clin Invest 88 1991 1760
6. A. Betz J. Hofsteenge S.R. Stone Interaction of the N-terminal region of hirudin with the active-site cleft of thrombin Biochemistry 31 1992 4557
7. J.A. Bittl J. Strony J.A. Brinker Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina N Engl J Med 333 1995 764
8. A.L. Bloom D.P. Thomas Haemostasis and Thrombosis ed 3 1994 Churchill Livingstone New York
9. W. Bode I. Mayr U. Baumann The refined 1.9 A crystal structure of human alpha-thrombin: Interaction with D-Phe-Pro-Arg chloromethylketone and significance of the tyr-pro-pro-trp insertion segment EMBO J 8 1989 3467
10. C.P. Cannon C.H. McCabe T.D. Henry A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial J Am Coll Cardiol 23 1994 993
11. R.W. Colman J. Hirsh V. Marder Hemostasis and Thrombosis: Basic Principles and Clinical Practice ed 3 1994 JB Lippincott Philadelphia
12. A.J. Connolly H. Ishihara M.L. Kahn Role of the thrombin receptor in development and evidence for a second receptor Nature 381 1996 516
13. J.J. Cook G.R. Sitko B. Bednar An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey Circulation 91 1995 2961
14. S.R. Coughlin T.-K.H. Vu D.T. Hung Characterization of a functional thrombin receptor. Issues and opportunities J Clin Invest 89 1992 351
15. J. Dodt U. Seemuller R. Maschler The complete covalent structure of hirudin. Localisation of the disulfide bonds Biol Chem Hoppe Seyler 366 1985 379
16. S. Ekman B.I. Eriksson S. Lindbratt Recombinant hirudin CGP 39393 15 mg (TM Revase-Ciba) is the most effective and safe prophylaxis of thromboembolic disease in patients undergoing total hip replacement Thromb Haemost 73 1995 1093
17. B.R. Erickson E.J. Topol Direct thrombin inhibitors in arterial thrombosis A.A. Sasahara J. Loscalzo New Therapeutic Agents in Thrombosis and Thrombolysis 1997 Marcel Dekker New York 169
18. B.I. Eriksson M. Baur S. Ekman Recombinant hirudin, desirudin (REVASC), is more effective than enoxaparin as prophylaxis of thromboembolic complications in patients undergoing total hip replacement [abstract] Thromb Haemost 77 suppl 1997 564
19. B.I. Eriksson S. Ekman P. Kalebo Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393 Lancet 347 1996 635
20. B.I. Eriksson P. Kalebo S. Eckman Direct thrombin inhibition with rec-hirudin (CGP 39393) as prophylaxis of thromboembolic complications after total hip replacement Thromb Haemost 72 1994 227
21. J. Fuchs C.P. Cannon Hirulog in the treatment of unstable angina: Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 Trial Circulation 92 1995 727
22. B. Furie B.C. Furie Molecular and cellular biology of blood coagulation N Engl J Med 326 1992 800
23. C.S. Gibbs S.E. Coutre M. Tsiang Conversion of thrombin into an anticoagulant by protein engineering Nature 378 1995 413
24. J.S. Ginsberg Management of venous thromboembolism N Engl J Med 335 1996 1816
25. J.S. Ginsberg M.T. Nurmohamed M. Gent Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery Circulation 90 1994 2385
26. T.J. Girard Tissue factor pathway inhibitor A.A. Sasahara J. Loscalzo New Therapeutic Agents in Thrombosis and Thrombolysis 1997 Marcel Dekker New York 225
27. T.J. Girard L.A. MacPhail K.M. Likert Inhibition of factor VIIa–tissue factor coagulation activity by a hybrid protein Science 248 1990 1421
28. H.K. Gold F.W. Torres H.D. Garabedian Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris J Am Coll Cardiol 21 1993 1039
29. A. Gruber S.R. Hanson A.B. Kelly Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis Circulation 82 1990 578
30. GUSTO Angiographic Investigators The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after myocardial infarction N Engl J Med 329 1993 1615
31. GUSTO IIa Investigators Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes Circulation 60 1994 1631
32. S.R. Hanson J.H. Griffin L.A. Harker Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates J Clin Invest 92 1993 2003
33. L.A. Harker S.R. Hanson A.B. Kelly Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists Thromb Haemost 74 1995 464
34. L.A. Harker S.R. Hanson A.B. Kelly Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation Thromb Haemost 78 1997 736
35. 4 integrin after carotid endarterectomy in non-human primates [abstract] Blood 88 1996 140a
36. L.A. Harker A. Lundell D.A. Dichek Reduction in vascular lesion formation (VLF) by hirudin secreted from retroviral-transduced confluent endothelial cells on vascular grafts in baboons [abstract] Thromb Haemost 77 suppl 1997 585
37. L.A. Harker K.G. Mann Thrombosis and fibrinolysis M. Verstraete V. Fuster E.J. Topol Cardiovascular Thrombosis: Thrombocardiology ed 2 1998 Lippincott-Raven Philadelphia 3
38. L.A. Harker J.M. Maraganore J. Hirsh Novel antithrombotic agents R.W. Colman J. Hirsh V.J. Marder Hemostasis and Thrombosis: Basic Principles and Clinical Practice ed 3 1994 JB Lippincott Philadelphia 1638
39. E.J. Haskel S.R. Torr K.C. Day Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor Circulation 84 1991 821
40. D.T. Hung T.-K.H. Vu N.A. Nelken Thrombin-induced events in non-platelet cells are mediated by the unique proteolytic mechanism established for the cloned platelet thrombin receptor J Cell Biol 116 1992 827
41. O. Iqbal B.E. Lewis Y. Rangel Monitoring the anticoagulant effects of argatroban during coronary angioplasty and stenting using a point of care dry reagent test card system and its comparison with ACT (hemotc and hemochron) [abstract] Thromb Haemost 77 suppl 1997 494
42. H. Ishihara A.J. Connolly D. Zeng Protease-activated receptor 3 is a second thrombin receptor in humans Nature 386 1997 502
43. Y. Jang L.A. Guzman A.M. Lincoff Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model Circulation 92 1995 3041
44. A.B. Kelly J.M. Maraganore P. Bourdon Antithrombotic effects of synthetic peptides targeting different functional domains of thrombin Proc Natl Acad Sci USA 89 1992 6040
45. A.B. Kelly U.M. Marzec W. Krupski Hirudin interruption of heparin-resistant arterial thrombus formation in baboons Blood 77 1991 1006
46. H. Kobayashi S. Suzuki S. Sakamoto Argatroban, a direct thrombin inhibitor versus heparin during and after percutaneous transluminal coronary angioplasty (PTCA) [abstract] Thromb Haemost 77 suppl 1997 494
47. S. Krishnaswamy K.A. Field T.S. Edgington Role of the membrane surface in the activation of human coagulation factor X J Biol Chem 267 1992 26110
48. L.V. Lee TIMI Investigators Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial Am J Cardiol 75 1995 7
49. L.L.K. Leung C.S. Gibbs Modulation of thrombin's precoagulant and anticoagulant properties Thromb Haemost 78 1997 577
50. B.E. Lewis E. Grassman L. Wrona Successful use of argatroban in coronary angioplasty in patients with heparin induced thrombocytopenia syndrome [abstract] Thromb Haemost 77 suppl 1997 494
51. R.-M. Lidon P. Theroux M. Juneau Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects Circulation 88 1993 1495
52. R.M. Lidon P. Theroux R. Bonan Hirulog as adjunctive therapy to streptokinase in acute myocardial infarction [abstract] J Am Coll Cardiol 21 suppl A 1993 419A
53. J. Loscalzo A.I. Schafer Thrombosis and Hemorrhage 1994 Blackwell Scientific Boston 1
54. A.B. Lumsden A.B. Kelly P.A. Schneider Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons Blood 81 1993 1762
55. S.L. Maki W. Ruf S. Huang Nematode anticoagulant protein C2 (C2): A potent inhibitor of factor VIIa/tissue factor complex (FVIIa/TF) requires an exosite on factor Xa (FXa) that overlaps a factor Va (FVa) binding site [abstract] Circulation 94 suppl 1 1996 I-694
56. J.M. Maraganore Direct thrombin inhibitors: Hirulog A.A. Sasahara J. Loscalzo New Therapeutic Agents in Thrombosis and Thrombolysis 1997 Marcel Dekker New York 191
57. J.M. Maraganore B. Chao M.L. Joseph Anticoagulant activity of synthetic hirudin peptides J Biol Chem 264 1989 8692
58. I. Maruyama H. Saito T. Matsuda Antithrombotic effect of recombinant soluble human thrombomodulin on disseminated intravascular coagulation [abstract] Zimmerman Conf Proc 1 1996 82
59. M. Moia F. Schiele M. Walker Treatment of acute deep vein thrombosis (DVT) by subcutaneous r-Hirudin (HBW 023): A multi-centre study Thromb Haemost 83 1995 1456
60. J.H. Morrissey H. Fakhrai T.S. Edgington Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade Cell 50 1987 129
61. V.P. Mutucumarana E.J. Duffy P. Lollar The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa: A fluorescence study J Biol Chem 267 1992 17012
62. K.L. Neuhaus W. Niederer J. Wagner HIT (Hirudin for the Improvement of Thrombolysis): Results of a dose escalation study [abstract] Circulation 88 suppl I 1993 I-292
63. K.L. Neuhaus R. von Essen U. Tebbe Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study Circulation 90 1994 1638
64. E.M. Nutt D. Jain A.B. Lenny Purification and characterization of recombinant antistasin: A leech-derived inhibitor of coagulation factor Xa Arch Biochem Biophys 285 1991 37
65. OASIS Investigators Comparison of hirudin with heparin and warfarin for control for unstable angina and non Q wave MI in a randomized controlled trial [abstract] Circulation 92 suppl I 1995 I-416
66. B. Potzsch K. Madlener C. Seelig Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass—assessment of the whole blood ecarin clotting time Thromb Haemost 77 1997 920
67. F.C. Riess N. Bleese J. Kormann Recombinant hirudin is a heparin alternative in cardiac surgery J Cardiothorac Vasc Anesth 11 1997 538
68. W.E. Rote G.L. Oldeschulte E.M. Dempsey Evaluation of a novel small protein inhibitor of the blood coagulation factor VIIa/tissue factor complex in animal models of arterial and venous thrombosis [abstract] Circulation 94 suppl 1 1996 I-695
69. R.J. Santulli C.K. Derian A.L. Darrow Evidence for the presence of a protease-activated receptor distinct from the thrombin receptor in human keratinocytes Proc Natl Acad Sci USA 92 1995 9151
70. P.W. Serruys J.-P.R. Herrman R. Simon A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty N Engl J Med 333 1995 757
71. J.A. Shafer Direct thrombin inhibitors: Active-site inhibitors of thrombin A.A. Sasahara J. Loscalzo New Therapeutic Agents in Thrombosis and Thrombolysis 1997 Marcel Dekker New York 143
72. G.V.R.K. Sharma D.E. Lapsley J.A. Vita Safety and efficacy of hirulog in patients with unstable angina [abstract] Circulation 86 suppl I 1992 I-386
73. E.J. Topol R. Bonan D. Jewitt Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty Circulation 87 1993 1622
74. E.J. Topol V. Fuster R.A. Harrington Recombinant hirudin for unstable angina pectoris Circulation 89 1994 1557
75. E.J. Topol GUSTO IIb Investigators A comparison of recombinant hirudin versus heparin for the treatment of acute coronary syndromes N Engl J Med 335 1996 775
76. M. Tsiang L.R. Paborsky W.-X. Li Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo Biochemistry 35 1996 16449
77. A.A. van den Boss J.W. Deckers G.R. Heyndrickx Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty Circulation 88 1993 2058
78. M. Verstraete Direct thrombin inhibitors: Appraisal of the antithrombotic/hemorrhagic balance Thromb Haemost 78 1997 357
79. R. Virchow Phlogose und Thrombose in Gefass-system R. Virchow Gesammlte Abhandelungen zur Wissenschaftlichen Medizin 1856 von Meidinger Sohn Frankfurt 458
80. G.P. Vlasuk Direct factor Xa inhibitors A.A. Sasahara J. Loscalzo New Therapeutic Agents in Thrombosis and Thrombolysis 1997 Marcel Dekker New York 261
81. T.-K.H. Vu D.T. Hung V.I. Wheaton Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation Cell 64 1991 1057
82. L. Waxman D.E. Smith K.E. Arcuri Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa Science 248 1990 593
83. J.I. Weitz J. Hirsh Overview of new developments in heparins, thrombin inhibitors, and other new and novel agents A.A. Sasahara J. Loscalzo New Therapeutic Agents in Thrombosis and Thrombolysis 1997 Marcel Dekker New York 77
84. J.I. Weitz M. Hudoba D. Massel Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III–independent inhibitors J Clin Invest 86 1990 385
85. H.D. White P.E. Aylward J.J. Frey A randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO) Circulation 96 1997 2155
86. T. Yokoyama A.B. Kelly U.M. Marzec Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates Circulation 92 1995 485